CureVac - Hauptforum Forum: Community User: NeulingImDAX

@ Jense29: Auf Reddit haben die das GARNICHT auf den Schirm. Das spricht niemand über CureVac

GSt 🤫😂

da isses ja.... mein Fähnchen

Vielleicht sollte man in den Ami Foren auch posten dass 400000000 schon verkauft sind wenn die Zulassung kommt

Ist Agreeemnt GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration. CureVac will be responsible for the preclinical- and clinical-development through Phase 1 trials of these projects, after which GSK will be responsible for further development and commercialisation. CureVac will be responsible for the GMP manufacturing of the product candidates, including for commercialisation, and will retain commercialisation rights for selected countries for all product candidates

Die glauben das sogar!

Ist agreement. Under the terms of the deal, GSK will make an equity investment in CureVac of £130m (€150m), representing close to a 10% stake, an upfront cash payment of £104m (€120m) and a one-time reimbursable payment of £26m (€30m) for manufacturing capacity reservation, upon certification of CureVac’s commercial scale manufacturing facility currently under construction in Germany.

Grööööhl

Oscar44 would you please Tell evrybody in the US/on the Nasdaq That Elon on his was to Mars is still in Berlin - which is from an american Point of view pretty close to Tübingen?😉 Thank you !

Leute.... DAS ist Börse! Ruhe bewahren. Nicht kaputt spekulieren! Vor dem Trade ja! Aber dann nicht dieses exzessive "Fly to the Moon" Gejubel. Wir haben eine Pandemie und FAKT zu wenig Impfstoff! Wir haben eine Firma die "MACHER" an der Spitze hat! Die Aktie verlief im Bereich der 80/85 Euro genau so wie jetzt. Also etwas Ruhe bewahren ;)

Jense29 GSK get zero from the first vaccine- the current vaccine and rabbies vaccine

Tganx jon, sounds good

Jense29 The revenue will be more like 20% GSK -80% Curevac GSK held 10% of Curevac shares- prior to the IPO GSK have to provide . see first agreement. The companies will combine their mRNA expertise on development opportunities across a range of infectious disease pathogens, selected with the potential to best leverage the advantages of this platform technology, while addressing significant unmet medical need and economic burden. "CureVac’s existing COVID-19 mRNA and rabies vaccines research programmes are not included in the collaboration announced today."

Ich kann diese Hosenscheisserei nicht mehr lesen🤮

Ja ist doch auch wichtig grosse zuverlässige Partner zu haben